Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

The review synthesizes evidence showing that ayahuasca's effects involve a delicate balance between two serotonin receptor types: 5-HT2A and 5-HT1A. This dual action appears crucial for understanding ...

As interest in psychedelic medicine grows, researchers have synthesized a decade of evidence to understand how ayahuasca ...

SF is a 50-year-old woman, counseled about the therapeutic use of psilocybin by her neurologist, who has participated in ...

The Pacalis team is a blend of industry and academic expertise, led by co-founder and Monash university alumnus Dr David Bibby as Chief Executive Officer, and co-founder Professor Chris Langmead, ...

Tucker says that "drug technologies that minimize or eliminate the hallucinogenic effect in molecules targeting the 5-HT2A receptor have the potential to become the gold standard in one or more ...

Dr. Tucker continued: "In our opinion, drug technologies that minimize or eliminate the hallucinogenic effect in molecules ...

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...

These compounds retain the therapeutic benefits of psilocybin while addressing its limitations related to stability and dosing. These novel derivatives act as serotonin receptor agonists, targeting ...

In addition, these analogs target serotonin receptors (5-HT2A, 5-HT2B, and 5-HT2C), which are critical in mood regulation and pain perception. The ester modifications introduced in these analogs ...